A comprehensive guide to omega-3s — from mechanisms of action to metabolic applications, dosing, and clinical assessment.
Omega-3 fatty acids are essential polyunsaturated fats that the human body cannot produce on its own. They must be obtained through diet or supplementation. There are three clinically important types — EPA and DHA from marine sources are the most biologically active, while ALA from plants is the dietary precursor with limited conversion.
Primary anti-inflammatory omega-3. Competes with arachidonic acid to reduce pro-inflammatory eicosanoids. Key for cardiovascular and metabolic health.
MARINE SOURCEStructurally critical for brain, nerve, and retinal tissue. Incorporated into cell membranes. Essential for neurological function and cognitive health.
MARINE SOURCEThe only essential omega-3 — the body cannot make it. Found in flaxseed, chia, and walnuts. Converts to EPA/DHA, but only at ~5–10% efficiency.
ESSENTIAL · PLANTEPA and DHA compete with arachidonic acid for COX and LOX enzymes, shifting eicosanoid production toward less inflammatory prostaglandins (PGE3) and generating resolvins and protectins that actively resolve inflammation.
Reduce hepatic VLDL synthesis, leading to significant triglyceride reduction. Modest HDL elevation and improved TG:HDL ratio — a surrogate marker for insulin resistance.
DHA incorporates into phospholipid bilayers, particularly in neuronal and retinal cells. This improves receptor sensitivity, signal transduction, and cellular communication.
Act as ligands for PPARα and PPARγ nuclear receptors, influencing fat oxidation, insulin sensitivity, adipokine production, and glucose metabolism at the transcriptional level.
| Clinical Area | Key Findings | Evidence |
|---|---|---|
| Triglycerides | ↓ 20–50% at 3–4 g/day EPA+DHA. Most consistent lipid effect. | STRONG |
| Cardiovascular Events | REDUCE-IT trial: icosapentaenoic acid 4 g/day significantly reduced MACE in statin-treated patients with elevated TG. | STRONG |
| NAFLD / MASLD | Reduces hepatic fat content. Improves liver enzyme profiles. Adjunct to lifestyle intervention. | MODERATE |
| Insulin Resistance | Improves HOMA-IR, fasting insulin. Enhances peripheral glucose uptake via membrane fluidity. | MODERATE |
| Blood Pressure | Modest antihypertensive effect (~2–3 mmHg systolic). Meaningful additive effect in hypertensive patients. | MODERATE |
| PCOS | Improves TG, insulin sensitivity, and androgen markers. Reduces testosterone and LH:FSH ratio. | MODERATE |
| Cognitive Health | DHA essential for neuronal membrane integrity. Association with lower dementia risk and depression improvement. | EMERGING |
| Inflammation | ↓ hsCRP, IL-6, TNF-α in metabolic syndrome and autoimmune conditions. | MODERATE |
Minimum intake for population-level cardiovascular benefit. Achievable through 2 servings of oily fish per week.
Standard secondary prevention target. Consistent with AHA recommendations for patients with known CVD.
Prescription-grade doses. Consider Vascepa (pure EPA) or prescription fish oil preparations at this level.
Optimal range for MASLD, insulin resistance, PCOS, and inflammatory metabolic conditions. Used in The Metabolic Medicine programme.
Many fish oil labels state the total fish oil content (e.g. 1000 mg per capsule) rather than the actual EPA+DHA content. A 1000 mg capsule may contain only 300 mg of EPA+DHA. Always read the nutritional breakdown and count EPA+DHA grams — not total fish oil — when assessing your dose.
Most patients are deficient. The average Western diet provides 100–200 mg/day EPA+DHA — a fraction of the therapeutic target. Assume deficiency unless tested.
ALA sources are not a substitute. Flaxseed oil, chia, and walnuts provide ALA only. The conversion to EPA/DHA is too inefficient (<10%) to achieve clinical outcomes.
Expect 8–12 weeks for measurable response. Triglycerides may improve within 4 weeks; inflammatory markers and insulin sensitivity take longer. Set realistic expectations with patients.
LDL-C monitoring in dyslipidaemia. While TG reliably falls, some ethyl ester formulations raise LDL-C. Use pure EPA (icosapentaenoic acid) formulations in patients where LDL is a concern.
Omega-3 is non-toxic. No established upper tolerable intake limit. High doses are used safely in clinical trials. The main concern at >3 g/day is antiplatelet effect.
Test, don't guess. The omega-3 index is the best objective measure. Target >8% for cardiovascular benefit. Most untested patients sit at 4–5%.
Founder of The Metabolic Medicine — an international metabolic health programme delivered worldwide via Zoom, integrating evidence-based nutrition, hormonal medicine, lifestyle intervention, and gut health.